18F-FDOPA: A multiple-target molecule

Journal of Nuclear Medicine

Volumn 50, Issue 12, 2009, Pages 1915-1918

  Minn, Heikki ^a   Kauhanen, Saila ^a   Seppänen, Marko ^a   Nuutila, Pirjo ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

18F FDOPA; Insulinoma; Molecular imaging; Neuroendocrine tumor; Oncology; PET

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 NAL3 OCTREOTIDE; 6 FLUORODOPA F 18; AMINO ACID DECARBOXYLASE; CARBIDOPA; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; LAT PROTEIN; LAT1 PROTEIN; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE;

ABDOMINAL TUMOR; BINDING AFFINITY; CANCER PATIENT; CANCER SCINTISCANNING; CARCINOID; CHROMAFFIN CELL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DECARBOXYLATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DOPAMINERGIC SYSTEM; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TUMOR; GENE OVEREXPRESSION; GLIOMA; HUMAN; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL HYPERPLASIA; PANCREAS TUMOR; PARAGANGLIOMA; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA; TUMOR DIFFERENTIATION; ADULT; ARTICLE; HYPERINSULINISM; METABOLISM; NEWBORN; RADIOGRAPHY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; BIOLOGICAL TRANSPORT; DIHYDROXYPHENYLALANINE; HUMANS; HYPERINSULINISM; INFANT, NEWBORN; NEUROENDOCRINE CELLS; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 73349104404     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.065664     Document Type: Review

References (25)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
2. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
3. Abood GJ, Go A, Malhotra D, Shoup M. The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg Clin North Am. 2009;89:249-266.
4. Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol. 2009;6:143-152.
5. 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22:406-416.
6. Chung K-F, Sicard F, Vukicevic V, et al. Isolation of neural crest derived chromaffin progenitors from adult adrenal medulla. Stem Cells. 2009;27:2602-2613.
7. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med. 2008;49(suppl):43S-63S.
8. Koopmans KP, Neels ON, Kema IP, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009;71:199-213.
9. 18F]fluoro-3,4-dihydroxy- L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res. 2008;68:7183-7190.
10. 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26:1489-1495.
11. 18F]-fluoro- L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin Nucl Med. 2007;37:440-450.
12. 18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573-586.
13. Havekes B, Lai EW, Corssmit EPM, Romijn JA, Timmers HJ, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging. 2008;52:419-429.
14. 2. Radiochim Acta. 2008;96:845-848.
15. 18F] fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009;16:255-265.
16. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513-519.
17. 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrin (Oxf). 2008;69:580-586.
18. 18F) positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab. 2009;94:1295-1301.
19. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431-1438.
20. 18F- dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524-531.
21. 18F-FDG PET-CT. Eur Radiol. 2009;19:1425-1434.
22. Kapoor RR, James C, Hussain K. Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. Nat Clin Pract Endocrinol Metab. 2009;5:101-112.
23. 18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism. Horm Res. 2008;70:65-72.
24. 18F-DOPA) positron emission tomography as a tool to localize an insulinoma or β-cell hyperplasia in adult patients. J Clin Endocrinol Metab. 2007;92:1237-1244.
25. 18F-dihydroxyphenylalanine positron emission tomography. J Clin Oncol. 2008;26:5307-5308.